- How do KOLs perceive Boehringer Ingelheim’s adalimumab biosimilar, Cyltezo?
- With three adalimumab biosimilars now approved in Europe, what concerns do prescribers have with regard to multiple biosimilar versions becoming available?
- How do KOLs view Sandoz’s Rixathon, the second rituximab biosimilar to enter the RA space in Europe?
- Celltrion is currently developing a subcutaneously administered infliximab biosimilar, but what need is there currently for a subcutaneous version of this product?
- What concerns might prescribers have regarding Celltrion’s subcutaneous infliximab biosimilar?